BLCO Stock Analysis: Bausch + Lomb | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 6.125m USD | 12M Return: 14.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.79M
EPS Trend: -82.7%
Qual. Beats: 1
Rev. Trend: 98.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bausch + Lomb Corporation (NYSE: BLCO) is a Canada-headquartered eye health company operating across more than a dozen countries. Founded in 1853 and spun off from Bausch Health Companies Inc., it sits within the GICS Health Care Supplies sub-industry and serves the global ophthalmology and vision care markets through three reporting segments.
The Vision Care segment offers contact lenses across the spectrum of wearing modalities, along with lens care products, eye vitamins, and over-the-counter drops for allergies, conjunctivitis, dry eye, and redness. The Pharmaceuticals segment provides both proprietary and generic products for post-operative care, glaucoma, ocular hypertension, eye inflammation, dry eyes, and retinal diseases. The Surgical segment supplies intraocular lenses, phacoemulsification equipment, and related instruments and consumables used in cataract, corneal, vitreous, and retinal procedures. Products are sold through direct sales forces and independent distributors.
- Alcon and J&J competition pressures daily disposable contact lens share
- Cataract surgical IOL volumes drive Surgical segment revenue growth
- XIPERE retinal drug uptake expands pharmaceutical segment margins
| Net Income: -219.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA 1.28 > 1.0 |
| NWC/Revenue: 18.36% < 20% (prev 20.05%; Δ -1.69% < -1%) |
| CFO/TA 0.02 > 3% & CFO 340.4m > Net Income -219.0m |
| Net Debt (4.80b) to EBITDA (649.0m): 7.40 < 3 |
| Current Ratio: 1.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (355.2m) vs 12m ago 0.68% < -2% |
| Gross Margin: 55.86% > 18% (prev 58.65%; Δ -2.79% > 0.5%) |
| Asset Turnover: 38.28% > 50% (prev 35.96%; Δ 2.32% > 0%) |
| Interest Coverage Ratio: 0.54 > 6 (EBIT TTM 233.0m / Interest Expense TTM 434.0m) |
| A: 0.07 (Total Current Assets 2.78b - Total Current Liabilities 1.82b) / Total Assets 13.8b |
| B: -0.07 (Retained Earnings -1.00b / Total Assets 13.8b) |
| C: 0.02 (EBIT TTM 233.0m / Avg Total Assets 13.6b) |
| D: 0.87 (Book Value of Equity 6.38b / Total Liabilities 7.33b) |
| Altman-Z'' = 1.25 = BB |
| DSRI: 1.02 (Receivables 1.11b/1.01b, Revenue 5.21b/4.83b) |
| GMI: 1.05 (GM 58.65% / 55.86%) |
| AQI: 0.98 (AQ_t 0.67 / AQ_t-1 0.68) |
| SGI: 1.08 (Revenue 5.21b / 4.83b) |
| TATA: -0.04 (NI -219.0m - CFO 340.4m) / TA 13.8b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 16.23 with a total of 220,592 shares traded. Over the past week, the price has changed by -5.42%, over one month by +6.36%, over three months by -1.58% and over the past year by +14.30%.
Current recommended Stop Loss: 15.60 (which is 3.9% or 1.4 ATR below the current price).
Bausch + Lomb has received a consensus analysts rating of 3.53. Therefore, it is recommended to hold BLCO.
- StrongBuy: 3
- Buy: 3
- Hold: 8
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 17.9 | 10.2% |
P/E Forward = 21.5983
P/S = 1.1761
P/B = 0.9591
P/EG = 0.8878
Revenue TTM = 5.21b USD
EBIT TTM = 233.0m USD
EBITDA TTM = 649.0m USD
Long Term Debt = 5.03b USD (from longTermDebt, last quarter)
Short Term Debt = 39.0m USD (from shortTermDebt, last quarter)
Debt = 5.07b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.80b USD (calculated: Debt 5.07b - CCE 268.0m)
Enterprise Value = 10.9b USD (6.13b + Debt 5.07b - CCE 268.0m)
Interest Coverage Ratio = 0.54 (Ebit TTM 233.0m / Interest Expense TTM 434.0m)
EV/FCF = 1000.0x (Enterprise Value 10.9b / FCF TTM 4.33m)
FCF Yield = 0.04% (FCF TTM 4.33m / Enterprise Value 10.9b)
FCF Margin = 0.08% (FCF TTM 4.33m / Revenue TTM 5.21b)
Net Margin = -4.21% (Net Income TTM -219.0m / Revenue TTM 5.21b)
Gross Margin = 55.86% ((Revenue TTM 5.21b - Cost of Revenue TTM 2.30b) / Revenue TTM)
Gross Margin QoQ = 56.59% (prev 58.08%)
Tobins Q-Ratio = 0.79 (Enterprise Value 10.9b / Total Assets 13.8b)
Interest Expense / Debt = 8.56% (Interest Expense 434.0m / Debt 5.07b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 184.1m (EBIT 233.0m * (1 - 21.00%))
Current Ratio = 1.53 (Total Current Assets 2.78b / Total Current Liabilities 1.82b)
Debt / Equity = 0.79 (Debt 5.07b / totalStockholderEquity, last quarter 6.38b)
Debt / EBITDA = 7.40 (Net Debt 4.80b / EBITDA 649.0m)
Debt / FCF = 1.11k (out of range, set to none) (Net Debt 4.80b / FCF TTM 4.33m)
Total Stockholder Equity = 6.42b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.61% (Net Income -219.0m / Total Assets 13.8b)
RoE = -3.41% (Net Income TTM -219.0m / Total Stockholder Equity 6.42b)
RoCE = 2.03% (EBIT 233.0m / Capital Employed (Equity 6.42b + L.T.Debt 5.03b))
RoIC = 1.57% (NOPAT 184.1m / Invested Capital 11.7b)
WACC = 8.05% (E(6.13b)/V(11.2b) * Re(9.12%) + D(5.07b)/V(11.2b) * Rd(8.56%) * (1-Tc(0.21)))
Discount Rate = 9.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.40 | Cagr: 0.56%
[DCF] Terminal Value 75.44% ; FCFF base≈4.33m ; Y1≈4.35m ; Y5≈4.60m
[DCF] Fair Price = N/A (negative equity: EV 71.6m - Net Debt 4.80b = -4.73b; debt exceeds intrinsic value)
EPS Correlation: -82.72 | EPS CAGR: -36.12% | SUE: 0.89 | # QB: 1
Revenue Correlation: 97.95 | Revenue CAGR: 11.17% | SUE: 0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.16 | Chg30d=+0.00% | Revisions=-8% | Analysts=13
EPS next Quarter (2026-09-30): EPS=0.22 | Chg30d=+0.37% | Revisions=-42% | Analysts=13
EPS current Year (2026-12-31): EPS=0.80 | Chg30d=+0.90% | Revisions=+44% | GrowthEPS=+57.6% | GrowthRev=+7.2%
EPS next Year (2027-12-31): EPS=1.08 | Chg30d=+1.24% | Revisions=+31% | GrowthEPS=+33.8% | GrowthRev=+5.7%
[Analyst] Revisions Ratio: +13% (up=25, down=19)